Insilico Medicine has agreed to a deepened collaboration with China Medical System Holdings (CMS) that could pay the AI-driven biotech up to roughly 1.2 billion yuan (about $177 million) in milestones and royalties to develop treatments for central nervous system diseases. The expanded partnership, announced in mid-July, targets a mass-market central nervous system indication built around a novel mechanism of action identified by Insilico's AI platform.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.